Hanmi Science Co

Hanmi Science Co Diluted EPS

The Diluted Earnings per Share of Hanmi Science Co (008930.KS) as of Oct 10, 2026 is 1,866.61 KRW. In the previous year, Diluted Earnings per Share was 937.04 KRW — a change of 99.20% (higher).

Diluted EPS

1,866.61KRW

YoY

99.20%

Last updated:

Diluted Earnings per Share of Hanmi Science Co is 2025 1,866.61 KRW. Diluted Earnings per Share of Hanmi Science Co was 2024 937.04 KRW. It decreases by 99.20% higher compared to the previous year.

The Hanmi Science Co Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
284.12 KRW
Jan 1, 2019
484.77 KRW
Jan 1, 2020
356.40 KRW
Jan 1, 2021
677.16 KRW
Jan 1, 2022
1,091.38 KRW
Jan 1, 2023
1,815.38 KRW
Jan 1, 2024
937.04 KRW
Jan 1, 2025
1,866.61 KRW
The Hanmi Science Co Diluted EPS history
YEARDiluted EPSYoY
1,866.61KRW+99.20%
937.04KRW-48.38%
1,815.38KRW+66.34%
1,091.38KRW+61.17%
677.16KRW+90.00%
356.40KRW-26.48%
484.77KRW+70.63%
284.12KRW-38.86%
464.73KRW+278.90%
122.65KRW-95.64%
2,815.14KRW+737.65%
336.08KRW—
Access this data via the Eulerpool API

Hanmi Science Co Stock analysis

What does Hanmi Science Co do? Hanmi Science Co Ltd is a South Korean company specializing in the manufacturing of pharmaceutical products, biologics, and medical devices. The company was founded in 1973 as a chemical company and obtained the license for drug manufacturing in 1990, expanding its product range to include pharmaceuticals. Today, the company's business model includes three main areas: research and development, manufacturing and sales of drugs, and sales of medical devices. Hanmi aims to develop and produce innovative and high-quality products to improve people's health worldwide. In the field of research and development, Hanmi Science is a leading company. It specializes in the research and development of novel drugs and biologics. The company has an impressive track record in the development and marketing of innovative drugs for the treatment of diabetes, cancer, and rare diseases. This includes a range of biosimilars produced using biotechnological methods that are more affordable compared to original medical substances. Hanmi also has a state-of-the-art production infrastructure that meets the highest quality standards and ensures reliable supply. In the field of drug manufacturing, the company produces generics and biosimilars that are sold in more than 50 countries worldwide. Hanmi also specializes in the production of chemotherapeutics and parenteral drugs that have proven efficacy and safety. The medical device sales division focuses on marketing high-quality medical devices, including diagnostic and monitoring devices used in the medical field. Hanmi also distributes a range of medical consumables, including transfusion sets, syringes, infusion sets, and catheters. Hanmi Science Co Ltd offers a wide range of products that can be categorized into various categories. Among the pharmaceutical products are antidiabetic drugs, anticancer agents, antidepressants, antibiotics, antiviral medications, and products for the treatment of rare diseases. The portfolio also includes biosimilars of botulinum toxin, insulin, and humiderm among the biologics. Overall, Hanmi Science Co Ltd holds a strong position in the South Korean market and has also established a good reputation internationally. With its focus on research and development and the production of high-quality drugs and medical devices, the company has a promising future. Hanmi Science Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hanmi Science Co stock

Diluted Earnings per Share of Hanmi Science Co is 1,866.61 KRW in 2025.

Diluted Earnings per Share of Hanmi Science Co changed from 937.04 KRW to 1,866.61 KRW, representing a 99.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Hanmi Science Co since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

Income Statement — Hanmi Science Co

All Key Metrics — Hanmi Science Co